Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07023640 for Malignant Neoplasms of Brain is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Back to Search
Peking Union Medical College HospitalApplication of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors 50 Novel Treatment
Clinical Trial NCT07023640 is an interventional study for Malignant Neoplasms of Brain that is recruiting. It started on 10 July 2025 with plans to enroll 50 participants. Led by Peking Union Medical College Hospital, it is expected to complete by 17 June 2026. The latest data from ClinicalTrials.gov was last updated on 5 August 2025.
Brief Summary
This study aims to perform ⁶⁸Ga-DOTA-mPNE PET/CT imaging in patients with clinically suspected or confirmed malignant tumors, in order to evaluate tracer uptake in lesions and analyze CD73 expression levels. In a subgroup of up to 10 participants, dynamic PET/CT imaging will be conducted for up to 90 minutes post-injection to assess the tracer's biodistribution and pharmacokinetic properties.Correlation analyses with...Show More
Official Title
Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors
Conditions
Malignant Neoplasms of BrainOther Study IDs
- PUMCH-CD73-3
NCT ID Number
Start Date (Actual)
2025-07-10
Last Update Posted
2025-08-05
Completion Date (Estimated)
2026-06-17
Enrollment (Estimated)
50
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Primary Purpose
Diagnostic
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalMalignant Neoplasms | 68Ga-DOTA-mPNE PET/CT examination was performed after intravenous injection of 68GA-DOTA-mPNE tracer |
Primary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
SUVmax | The area of interest was delineated and the SUVmax value was measured by using the post-processing software built into the acquisition machine. | Time Frame: Day 1 (on the day of PET/CT imaging) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
- Age ≥18 years, with an expected survival of ≥12 weeks.
- No prior radiotherapy or chemotherapy; eligible for surgery or biopsy to obtain pathological diagnosis.
- At least one measurable target lesion according to RECIST version 1.1 (Response Evaluation Criteria in Solid Tumors).
- Written informed consent obtained and able to comply with follow-up requirements.
- Severe hepatic or renal dysfunction.
- Women who are planning to conceive, currently pregnant, breastfeeding, or intend to have children during the study period are not eligible. Fertile participants must use effective contraception during the study.
- Unable to lie flat for 30 minutes.
- Refusal to participate in this clinical study.
- Claustrophobia or other psychiatric disorders.
- Any other condition deemed unsuitable for study participation by the investigator.
Peking Union Medical College Hospital482 active studies to exploreStudy Central Contact
Contact: Chenhao Jia, M.D., 18548703382, [email protected]
1 Study Locations in 1 Countries
Beijing Municipality
Peking Union Medical College Hospital, Beijing, Beijing Municipality, 100730, China
Chenhao Jia, M.D., Contact, 18548703382, [email protected]
Recruiting